Mina Abdolahi1, Elmira Karimi2, Payam Sarraf3,4, Abbas Tafakhori3,4, Goli Siri5, Farahnaz Salehinia5, Mohsen Sedighiyan6, Behzad Asanjarani5, Mostafa Badeli7, Hamed Abdollahi8, Niyoosha Yoosefi9, Abolghasem Yousefi8, Amir Shayegan Rad6, Mahmoud Djalali10. 1. Amir Alam Hospital Complexes, Tehran University of Medical Sciences, Sa'adi Street, Tehran, Iran. 2. Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Poursina Street, Tehran, Iran. 3. Iranian Centre of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. 4. Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran. 5. Department of Internal Medicine, Amiralam Hospital, Tehran University of Medical Sciences, Tehran, Iran. 6. Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Poursina Street, PO Box: 14155-6446, Tehran, Iran. 7. Department of Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Poursina Street, Tehran, Iran. 8. Department of Anesthesiology, Amir Alam Hospital Complexes, Tehran University of Medical Sciences, Sa'adi Street, Tehran, Iran. 9. Honours Cellular Anatomical Physiology, University of British Columbia, Vancouver, BC, Canada. 10. Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Poursina Street, PO Box: 14155-6446, Tehran, Iran. mjalali87@yahoo.com.
Abstract
OBJECTIVE: The purpose of this clinical trial was to examine the effect of omega-3 fatty acids (W-3 FAs), nanocurcumin and their combination on serum levels and gene expression of VCAM in patients with episodic migraine. RESULTS: In this study, 80 patients were randomly divided in to 4 groups to receive for 2 months. Both serum levels and gene expression of VCAM showed remarkable decreases after single W-3 and after combined W-3 and nanocurcumin interventions. However, a borderline significant change and no remarkable change were observed after single nanocurcumin supplementation and in control group, respectively. While a significant difference between study groups in VCAM concentrations existed, there was no meaningful difference in VCAM gene expression among groups. It appears that the W-3 and combined W-3 and nanocurcumin can relieve VCAM serum level and its gene expression in patients with episodic migraine. Moreover, the combination of W-3 with nanocurcumin might cause more significant declines in VCAM level in the serum of migraine patients than when W-3 is administered alone. TRIAL REGISTRATION: This study was registered in Iranian Registry of Clinical Trials (IRCT) with ID number: NCT02532023.
RCT Entities:
OBJECTIVE: The purpose of this clinical trial was to examine the effect of omega-3 fatty acids (W-3 FAs), nanocurcumin and their combination on serum levels and gene expression of VCAM in patients with episodic migraine. RESULTS: In this study, 80 patients were randomly divided in to 4 groups to receive for 2 months. Both serum levels and gene expression of VCAM showed remarkable decreases after single W-3 and after combined W-3 and nanocurcumin interventions. However, a borderline significant change and no remarkable change were observed after single nanocurcumin supplementation and in control group, respectively. While a significant difference between study groups in VCAM concentrations existed, there was no meaningful difference in VCAM gene expression among groups. It appears that the W-3 and combined W-3 and nanocurcumin can relieve VCAM serum level and its gene expression in patients with episodic migraine. Moreover, the combination of W-3 with nanocurcumin might cause more significant declines in VCAM level in the serum of migrainepatients than when W-3 is administered alone. TRIAL REGISTRATION: This study was registered in Iranian Registry of Clinical Trials (IRCT) with ID number: NCT02532023.
Authors: Elisa Brietzke; Rodrigo B Mansur; Rodrigo Grassi-Oliveira; Joanna K Soczynska; Roger S McIntyre Journal: Med Hypotheses Date: 2012-02-25 Impact factor: 1.538
Authors: Giorgio Lambru; Anna P Andreou; Martina Guglielmetti; Paolo Martelletti Journal: Expert Opin Emerg Drugs Date: 2018-11-30 Impact factor: 4.191
Authors: Francisco Javier Manzano-Moreno; Victor Javier Costela-Ruiz; Lucía Melguizo-Rodríguez; Rebeca Illescas-Montes; Olga García-Martínez; Concepción Ruiz; Javier Ramos-Torrecillas Journal: Arch Oral Biol Date: 2018-05-09 Impact factor: 2.633
Authors: Marcos F DosSantos; Rosenilde C Holanda-Afonso; Rodrigo L Lima; Alexandre F DaSilva; Vivaldo Moura-Neto Journal: Front Cell Neurosci Date: 2014-10-08 Impact factor: 5.505